BCLIOQBHealthcare

Brainstorm Cell Therapeutics Inc.

Reports in 15d· 2026-05-14

+6.3% · 90d

$0.67

-0.12 (-15.41%)

News

No News Yet

Press releases and SEC filings for BCLI will appear here as they are published.

Check back later for updates

Key Data

Market Cap$7.4M

Open$0.84

Prev Close$0.79

Day Range$0.63 – $0.84

52W Range$0.46 – $1.92

Volume9,902

P/E (TTM)—

EPS$-1.11

Dividend Yield—

Beta0.46

Next Earnings2026-05-14(15d)

About

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Healthcare · Biotechnology

20 employees

www.brainstorm-cell.com